Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • rdsqc22
    Junior Member
    • Nov 2013
    • 7

    #1

    Unsure how to use GAGE with biological replicates

    Hello,

    I have some RNAseq data (cuffdiff) that I am trying to run gage/pathview on, to determine which pathways are enriched. However, my data set uses biological replicates (two samples of each cell type), which I have not used before with gage.

    I read the manuals and found a mention of a 'weights' argument for gage here: http://www.bioconductor.org/packages...e/man/gage.pdf
    But it does not describe what the numberic vector to be the weight should contain or how to determine it based on the number of replicates. While there are many other examples of how to use gage/pathview on the Bioconductor website, none of them mention the 'weights' argument or any sort of replicates.

    The command I used without biological replicates is:
    > fc.kegg.p <- gage(exp.fc, gsets = kegg.sets.rn, ref = NULL, samp = NULL)

    Does anyone have any experience with this? How would I go about analyzing these data?
  • bigmw
    Senior Member
    • Aug 2013
    • 124

    #2
    When you expression data are differential expression score like fold changes, no matter with or without replicate (matrix or vector), you can use gage with ref=NULL and samp=NULL. If you data are the original expression levels, you should specify the column numbers of control(s) and experiment(s) in your data matrix with ref and samp. If your column 1-2 are controls, and 3-4 are experiments, the samples are not paired, you can do something like:
    kegg.p <- gage(exp.data, gsets = kegg.sets.rn, ref = 1:2, samp = 3:4, compare = "unpaired")

    check gage function document for details:
    ?gage
    you may also want to check the quick start and basic analysis sections in gage tutorial:

    Comment

    • rdsqc22
      Junior Member
      • Nov 2013
      • 7

      #3
      My data are the cuffdiff output for two samples each of four different cell types. I had already been using the (very helpful) tutorial you linked, which explains how to retrieve the needed data from the gene_exp.diff file of the cuffdiff output. This file, though, will combine the data for biolofigal replicates, making it impossible to do what you describe with multiple columns. This is why I was interested in the 'weights' argument.

      There is a file with the cuffdiff output, 'genes.read_group_tracking', which does list FPKM for each gene for each replicate. Perhaps I should use that.

      I don't see how gage will still be statistically accurate when working with fold changes with biological replicates without specifying them. If there are multiple biological replicates, then a fold change of a certain amount should be more significant than a fold change of the same amount with only one sample of each cell type. Could you elaborate on how that works?

      Comment

      • bigmw
        Senior Member
        • Aug 2013
        • 124

        #4
        GAGE does take sample size into account. It does pair-wise comparison between experiments vs controls (disease vs normal etc), i.e. conducts gene set or pathway test between each sample pairs and then summarizes the results. The more samples (hence independent experiment-control sample pairs) you have, the more testing power you get this way. You may also read the GAGE paper for more details of the method, at http://www.biomedcentral.com/1471-2105/10/161.
        So to take the advantages of the full testing power of GAGE, it is recommended to follow the native workflow. OR you can use the normalized data from other tools (like the FPKM for each gene for each replicate by cuffdiff), then feed the data into GAGE as mentioned above. The joint workflows are there for users’ convenience. People can do the differential expression analysis (at individual gene level) with well established tools like DESeq, edgeR, Cufflinks etc and input the results into GAGE/Pathview workflow for pathway analysis and visualization. It is convenient, however less sensitive because sample size is not considered this way.
        People asked similar questions previously:
        Discussion of next-gen sequencing related bioinformatics: resources, algorithms, open source efforts, etc

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, Today, 02:55 AM
        0 responses
        4 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-24-2026, 12:17 PM
        0 responses
        10 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-23-2026, 11:41 AM
        0 responses
        11 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-20-2026, 11:10 AM
        0 responses
        23 views
        0 reactions
        Last Post SEQadmin2  
        Working...